Roche has 19 investigational medicines that could launch by 2030—and even if not all of them make it to market, the company is “well set-up for growth into the next decade,” CEO Thomas Schinecker said on the pharma’s Q2 earnings call.
Roche’s late stage pipeline ‘so full,’ CEO Schinecker not feeling pressure to add on